Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | SLC10A2 | Q12908 | 14/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227194 | 1.00 | NR1H4 (0.48) | NR1H4SLC10A2KMT2AMEN1POLB | |
| SCHEMBL5227198 | 1.00 | NR1H4 (0.48) | NR1H4SLC10A2KMT2AMEN1POLB | |
| SCHEMBL14559673 | 0.97 | NR1H4 (0.49) | NR1H4SLC10A2KMT2AMEN1POLB | |
| SCHEMBL14559669 | 0.97 | NR1H4 (0.49) | NR1H4SLC10A2KMT2AMEN1POLB | |
| SCHEMBL5223220 | 0.95 | NR1H4 (0.47) | NR1H4SLC10A2 | |
| SCHEMBL7093635 | 0.95 | NR1H4 (0.47) | NR1H4SLC10A2 | |
| SCHEMBL3808828 | 0.95 | NR1H4 (0.47) | NR1H4SLC10A2 | |
| SCHEMBL5223216 | 0.95 | NR1H4 (0.47) | NR1H4SLC10A2 | |
| SCHEMBL14559662 | 0.93 | NR1H4 (0.55) | NR1H4SLC10A2KMT2AMEN1POLB | |
| SCHEMBL7051076 | 0.93 | NR1H4 (0.42) | NR1H4SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | claimed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | claimed |
| EP-1430040-B1 | BENZOTHIAZEPINE DERIVATIVES | ALBIREO AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| EP-1345918-B1 | 1,5 BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-7192946-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-7192945-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-20040254160-A1 | Benzothiazepine derivatives | ELOBIX AB (SE) | 2004-12-16 | — | — | US | disclosed |
| US-20040067933-A1 | Chemical compounds | ELOBIX AB (SE) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | NR1H4 378/4885SLC10A2 2257/4885KMT2A 2900/4885 |
| US-20040067933-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | NR1H4 7/4885SLC10A2 1/4885KMT2A 2975/4885 |
| US-20040254160-A1 | Benzothiazepine derivatives | SLC10A2, SLC10A1, ABCB11 | NR1H4 6/4885SLC10A2 1/4885KMT2A 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.